KRAS and pancreatic ductal adenocarcinoma: RAGE and its ligands also play vital roles in pancreatic ductal adenocarcinoma (PDAC) by increasing NF-κB activity and may be directly activated RAS which KRAS oncogenic mutations are observed in up to 30% of all cancers and in PDAC KRAS mutation is in nearly all tumors [194].